Home Journals Articles Updates About
CN
image
收藏切换
Immunological and metabolic optimization of tumor neoantigen vaccines
收藏切换
PDF
Xiafeng Wang, Zhangping Huang, Lin Peng, Shuoxi Xu, Jianfeng Huang, Ji Wang
Cancer Biology & Medicine | 2025, 22(11) : 1275 - 1281
Less
收藏切换
Cancer Biology & Medicine | 2025, 22(11): 1275-1281
• PERSPECTIVE •
Immunological and metabolic optimization of tumor neoantigen vaccines
Full
Xiafeng Wang, Zhangping Huang, Lin Peng, Shuoxi Xu, Jianfeng Huang, Ji Wang
Affiliations
  • Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 440100, China
Published: 2025-11-15 doi: 10.20892/j.issn.2095-3941.2025.0445
Outline
收藏切换
Xiafeng Wang, Zhangping Huang, Lin Peng, Shuoxi Xu, Jianfeng Huang, Ji Wang. Immunological and metabolic optimization of tumor neoantigen vaccines[J]. Cancer Biology & Medicine, 2025 , 22 (11) : 1275 -1281 . DOI: 10.20892/j.issn.2095-3941.2025.0445
Full Text
Less
Tumor initiation and progression are highly intricate biological processes, and mutation-driven tumorigenesis is a primary underlying cause. Personalized cancer vaccines have been developed to exploit these specific mutations, particularly in the form of tumor neoantigens, to induce immune responses, particularly the activation of CD8+ T cells, which can attack malignant cells. Since tumor mutations result in protein sequence alterations distinct from those in normal tissues, therapies that precisely target these alterations could, in principle, confer effective tumor control while minimizing off-target effects.
Neoantigen-based therapies have garnered considerable scientific and clinical attention in recent years, as evidenced by more than 100 active or completed clinical trials. To date, a diverse array of neoantigen-targeting vaccine platforms have advanced to clinical trials, including peptide, DNA, RNA, and viral vector-based vaccines, each with their own advantages and limitations (Table 1). Notably, more than 50% of these trials have used synthetic long peptides (SLPs) in combination with adjuvants, typically poly-ICLC. Although these platforms can induce CD4+ T cell immune responses, their inherently low immunogenicity for CD8+ T cells remains a major challenge. Typically, neoantigen-specific CD8+ T cells are either undetectable or present at very low frequencies, accounting for 0.1% of the total CD8+ T cells in the peripheral blood. This proportion is far below the 10%–20% rate achievable with highly immunogenic vaccines such as the yellow fever and vaccinia vaccine1. Although the magnitude of CD8+ T cells is not the sole factor determining clinical outcomes, it is foundational to therapeutic efficacy. Sufficient CD8+ T cells are necessary for the effectiveness of other therapies aimed at reversing exhaustion and the immunosuppressive tumor microenvironment (TME).
This Perspective reviews current advances and ongoing challenges (Table 2) in the development of tumor neoantigen vaccines. Specifically, the efficacy of tumor vaccines is influenced by factors within the TME, such as metabolism, whose crucial role has been progressively elucidated in recent years; this aspect is also summarized and discussed. Finally, strategies for enhancing tumor neoantigen vaccines are described (Figure 1).
Sources of neoantigens
Less
Tumor neoantigens originate primarily from mutation-dependent tumor antigens. Because of tumors’ intrinsic heterogeneity, substantial variability exists in neoantigen expression, thus leading to inconsistent neoantigen presentation. Therefore, the identification of so-called “trunk mutations” that prominently control tumor proliferation has become critical. However, a major challenge arises from the high similarity between these trunk mutations and their corresponding wild-type sequences. During T cell development, neoantigen-specific T cell receptors (TCRs) often exhibit inherently low affinity for such neoantigens with minimally altered peptide sequences due to negative selection. Even when high-affinity TCRs do exist, the absolute abundance of such T cells remains extremely low2. This mechanistic insight helps explain why neoantigen-specific CD8+ T cell responses are often undetected or are observed at only very low levels in patients, although the possible induction of immune responses against such antigens may occur.
Beyond mutation-driven antigens, an alternative source of tumor neoantigens comes from mutation-independent mechanisms involving antigens derived from non-coding genomic regions. Their generation can occur through various pathways, such as the translation of circular RNAs, initiation from selective non-AUG start codons, and ribosomal frameshift errors3. Because some of these antigens exhibit substantial tumor specificity, they might potentially provide a rich source for novel immunotherapeutic targets. Notably, a recent study has revealed that such cryptic neoantigens can elicit effective cytotoxic responses against pancreatic cancer organoids4. However, notable challenges lie in the heterogeneous expression of these non-canonical antigen epitopes across tumor clones, coupled with their dispensability for tumor cell survival. These characteristics render them inherently susceptible to immune editing and facilitate vaccine escape in the absence of robust epitope spreading. Consequently, although targeting this “dark proteome” offers compelling opportunities, its overall clinical utility remains to be rigorously validated.
Neoantigen identification and design
Less
The advent of next-generation sequencing technologies has made large-scale genetic analysis of individual tumors and patients feasible. Coupled with advances in whole-exome sequencing and RNA sequencing, a wide range of bioinformatics pipelines and MHC-peptide binding prediction algorithms have been developed for the prospective identification of tumor neoantigens. Some predictive tools integrate multiple considerations, such as antigen cleavage, antigen transport, cellular presentation, and TCR recognition. In recent years, new artificial intelligence technologies have also been applied to enhance accuracy.
Despite these technical advancements, the practical effectiveness of these bioinformatics approaches remains limited. In some cases, less than 2.7% of predicted neoantigens are ultimately recognized by patient-derived T cells5. Similarly, the Tumor Neoantigen Selection Alliance (TESLA) global consortium has reported that, even with a comprehensive pipeline—starting with MHC binding prediction and followed by validation using patient-matched T cells—only approximately 6% of the predicted neoantigens elicit T cell recognition6. These findings illustrate the limitations of current methods in tumor neoantigen prediction and highlight the urgent need for improved algorithms and validation frameworks.
The accuracy of neoantigen prediction depends not only on the sophistication of the computational algorithms but also critically on intrinsic biological factors pertaining to the tumor cells, antigen-presenting cells, and antigen processing preferences. Therefore, complementary approaches enabling direct integration of mass spectrometry immunopeptidomics data might provide better results. For instance, the NeoDis computational framework integrates data from genomic, transcriptomic, and immunopeptidomic sources to accurately identify neoantigens. Among the 66 HLA-I neoantigenic peptides for T cell screening assays, 11 were found to be immunogenic7. Nevertheless, these direct detection methods face their own technical challenges, including immunopeptidome dilution due to non-tumor cells infiltration, the requirement for large quantities of tumor tissue or cells, and frequently low MHC class I expression on tumor cells. These challenges might be potentially overcome by strategies such as cultivating tumor organoids to enrich for homologous peptides or using methods to enhance MHC class I expression8.
Adjuvants for tumor neoantigen vaccines
Less
Because of the inherently low immunogenicity of tumor neoantigens, administration of the antigen alone is generally insufficient to provoke robust immune response, thereby necessitating a combination of adjuvants. Certain vaccine platforms, such as plasmid DNA and mRNA-based vaccines, can partially function as self-adjuvants and boost the immune response, whereas SLP neoantigen vaccines require the addition of adjuvants to achieve effective immunogenicity. An adjuvant is an additive to vaccines that enhances the immunogenicity of antigens, common adjuvants include ligands of pattern recognition receptors, cytokines, and immune checkpoint inhibitors.
In recent years, extensive researches have focused on the roles of pattern recognition receptors, such as Toll-like receptors, and the cGAS-STING pathway. Ligands targeting these receptors are typically small molecules with well-defined mechanisms of action and favorable drug potential, and therefore highly promising for clinical translation. SLP neoantigen vaccines critically require dendritic cell (DC)-mediated antigen cross-presentation to effectively elicit CD8+ T cell immune responses. However, in the absence of adequate adjuvant support, mobilizing DCs to achieve potent T cell activation and expansion remains difficult. Inadequate DC activation can even lead to undesirable immune tolerance, thereby diminishing CD8+ T cell responses.
To circumvent this limitation, neopeptides are frequently co-administered with adjuvants. Nonetheless, the enhanced immunogenicity achieved through adjuvant addition is often modest and falls short of the robust and durable immune responses required for effective tumor control. This shortcoming arises from a predominant focus on the adjuvant’s immunostimulatory function, without adequately addressing the inherent inefficiency of the cross-presentation process itself. Crucially, because the cross-presentation process of exogenous antigens by DCs is inherently intricate and often inefficient, effectively presenting neoantigen epitopes is difficult. Therefore, to stimulate high-level specific CD8+ T cell immune responses to an extent comparable level to those induced by viral vaccines, not only adjuvant activity but also antigen cross-presentation by DCs must be optimized9.
Our recent study has offered new insights to address this important issue. We have developed a new series of STING agonists, collectively termed STING Agonist-Based ER targeting molecules (SABER), to not only potently activate DCs but also critically target antigens directly to the endoplasmic reticulum (ER). These characteristics depend on SABER’s high binding affinity toward the STING protein, which resides within the ER, a critical hub for antigen processing. Our findings have demonstrated that after neoantigens delivered to the ER, they can form a localized “micro-reactor” that effectively promotes antigen cleavage and transport. This mechanism subsequently augments the specific CD8+ T cell immune response. Compared with conventional adjuvanted SLPs, SABER-based neoantigen vaccines induce tenfold greater CD8+ T cell induction. Our findings strongly suggest that the “last mile” of antigen delivery, specifically from the cytoplasm to the ER, is crucial for optimizing antigen cross-presentation10.
Delivery system for tumor neoantigen vaccines
Less
Beyond the essential role of adjuvants, delivery systems are equally important for enhancing the T-cell immune response to neoantigens. In recent years, mRNA has attracted considerable attention, because of its rapid production and broad therapeutic scope across a diverse array of diseases. Despite its advantages, mRNA’s inherent instability and negative charge present major obstacles to efficient cellular uptake and membrane translocation. Consequently, encapsulation and transport via lipid nanoparticles (LNPs) have become imperative. LNPs not only protect mRNA against rapid degradation in vivo but also notably target antigen-presenting cells, which have a propensity for nanoparticle phagocytosis. Moreover, by precisely modulating the lipid composition and physicochemical properties of LNPs, organ and tissue-specific targeting can be optimized11. For instance, our research group has successfully used biomimetic nanoparticles to encapsulate 2′,3′-cyclic guanosine monophosphate–adenosine monophosphate, the natural ligand for the STING protein, thereby eliciting effective antigen-specific CD8+ T cell immunity in the lungs12. Additionally, the use of polymeric materials or inorganic nanoparticles has also been demonstrated to effectively enhance CD8+ T cell induction. However, a key impediment is the safety profiles of these delivery systems, particularly concerns regarding off-target organ accumulation and the potential induction of undesirable nanoparticle-triggered antibody or inflammatory responses. Therefore, we developed an in vivo electroporation system as an alternative delivery system13,14.
Metabolic effects on tumor neoantigen vaccines
Less
Despite substantial progress in tumor neoantigen vaccines, some post-injection challenges must be addressed to achieve meaningful clinical outcomes. These obstacles include tumor immune evasion, immunosuppressive TME, and T cell exhaustion. Recent evidence has highlighted the critical roles of metabolic changes in shaping the immune landscape of neoantigen-based vaccines. These metabolic alterations affect key processes, such as antigen presentation in tumor cells and DCs, as well as the overall state of T cells.
The immunopeptidome is highly plastic and is modulated by cellular metabolic activity. For example, altering cellular metabolism via inhibiting the mammalian target of rapamycin (mTOR) results in dynamic changes in the composition of the immunopeptidome and leads to high abundance of MHC class I-presented peptides15. Furthermore, autophagy, a key metabolic process in the degradation and recycling of various cytoplasmic components, enhances antigen processing in antigen-presenting cells. Notably, active autophagy facilitates the delivery of cytosolic antigens to MHC class II loading compartments, thereby promoting CD4+ T cell responses to intracellular antigens16.
Metabolic shifts in tumors frequently result in a highly immunosuppressive TME. Accumulated lactate, a byproduct of aerobic glycolysis, inhibits DC functions which are essential for effective T cell priming. Moreover, lactate-driven acidosis destabilizes peptide–MHC class I complexes and impairs antigen presentation, particularly via the cross-presentation pathway17. Cross-presentation is an energy-intensive process sensitive to the metabolic fitness of DCs. Recent studies have demonstrated that optimal cross-presentation requires finely tuned metabolic programs, including glycolysis, oxidative phosphorylation, and fatty acid metabolism18. Nevertheless, aberrant lipid accumulation in tumor-infiltrating DCs impairs their ability to present antigens, whereas pharmacological inhibition of fatty acid synthesis has been shown to substantially enhance the efficacy of cancer vaccines19.
In parallel, T cell metabolism, which underpins the effector function of CD8+ T cells responding to neoantigen vaccines, is also governed by nutrient availability within the TME. Notably, recent findings have revealed that lactate, rather than being merely immunosuppressive, also serves as a bioenergetic and biosynthetic fuel that supports CD8+ T cell activity in certain metabolic contexts20.
Conclusion and future prospects
Less
The identification and subsequent utilization of tumor neoantigens have led to paradigm shift in the understanding of malignancies and are highly promising avenue for cancer immunotherapy. Nevertheless, despite these bright prospects, substantial challenges persist. A major obstacle is that the high-level similarity between neoantigens and their wild-type counterparts often renders neoantigens poor immunogenicity and makes them concealed from the immune system. Consequently, stimulating comparably robust immune responses to those elicited by potent foreign substances, such as viruses, is inherently difficult.
Although bioinformatics approaches based on whole-exome sequencing and RNA sequencing have rapidly advanced, their predictive accuracy requires further refinement. Future developments are expected to rely on the seamless integration of machine learning and big data analytics to discern broader spectrum of epitope features, alongside the application of immunopeptidomics to more precisely identify antigen sequences. Moreover, ongoing advancements in mass spectrometry and organoid culture technologies are expected to facilitate the discovery of novel neoantigen epitopes.
Crucially, antigen optimization alone is insufficient, because the inherently low immunogenicity of neoantigens limits the host’s ability to mount robust, antigen-specific CD8+ T cell responses. Consequently, optimization of adjuvants and delivery systems is imperative. Although many adjuvants and delivery systems have been developed to date, their overall efficacy remains constrained. The immunostimulatory bias inherent to various adjuvants requires evaluation; moreover, most delivery systems function primarily at the organ or tissue level, and therefore fall short of achieving precise subcellular antigen delivery. Therefore, future efforts must focus on refining adjuvant structures and identifying more efficacious adjuvant combinations, also improving delivery systems that significantly enhance cross-presentation efficiency.
Furthermore, to overcome the overarching challenges inherent in tumor treatment, post-vaccination bottlenecks must be addressed. Metabolic reprogramming in tumor cells and the TME establishes a hostile immunological niche that adversely affects nearly every step involved in neoantigen vaccine efficacy, from antigen generation to cross-presentation and T cell activation. To fully harness the therapeutic potential of neoantigen-based cancer vaccines, these metabolic barriers must be overcome through rational combinatorial strategies that modulate both tumor-intrinsic and microenvironmental metabolic constraints.
In summary, substantial progress has been made in the identification of tumor neoantigens and the development of novel technologies to induce effective neoantigen-specific CD8+ T cell responses. However, multiple impediments persist, particularly regarding vaccine delivery and anti-tumor efficacy. Addressing these limitations through innovative and integrated strategies will be essential to fully achieve the clinical potential of neoantigen vaccines and deliver meaningful therapeutic benefits to patients with cancer.
References
Less
1.
Katsikis PD, Ishii KJ, Schliehe C.Challenges in developing personalized neoantigen cancer vaccines.Nat Rev Immunol. 2024; 24: 213–27.
2.
Stone JD, Harris DT, Kranz DM.TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.Curr Opin Immunol. 2015; 33: 16–22.
3.
Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, et al.Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides.Nature. 2024; 625: 593–602.
4.
Ely ZA, Kulstad ZJ, Gunaydin G, Addepalli S, Verzani EK, Casarrubios M, et al.Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition.Science. 2025; 388: eadk3487.
5.
Bjerregaard A-M, Nielsen M, Jurtz V, Barra CM, Hadrup SR, Szallasi Z, et al.An analysis of natural T cell responses to predicted tumor neoepitopes.Front Immunol. 2017; 8: 1566.
6.
Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, et al.Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction.Cell. 2020; 183: 818–34.e13.
7.
Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J, et al.A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy.Nat Biotechnol. 2025; 43: 1360–72.
8.
Demmers LC, Kretzschmar K, Van Hoeck A, Bar-Epraïm YE, van den Toorn HWP, Koomen M, et al.Single-cell derived tumor organoids display diversity in HLA class I peptide presentation.Nat Commun. 2020; 11: 5338.
9.
Wang J, Xie X, Jiang S, Lu L.Immunoengineered adjuvants for universal vaccines against respiratory viruses.Fundam Res. 2021; 1: 189–92.
10.
Wang X, Huang Z, Xing L, Shang L, Jiang J, Deng C, et al.STING agonist-based ER-targeting molecules boost antigen cross-presentation.Nature. 2025; 641: 202–10.
11.
Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D.Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects.Nat Rev Clin Oncol. 2023; 20: 739–54.
12.
Wang J, Li P, Yu Y, Fu Y, Jiang H, Lu M, et al.Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity.Science. 2020; 367: eaau0810.
13.
Li Y, Mo J, Liu J, Liang Y, Deng C, Huang Z, et al.A micro-electroporation/electrophoresis-based vaccine screening system reveals the impact of vaccination orders on cross-protective immunity.iScience. 2023; 26: 108086.
14.
Liu X, Jiang J, Liu J, Yang H, Huang Z, Deng C, et al.Nanoneedle array-electroporation facilitates intranuclear ribonucleoprotein delivery and high throughput gene editing.Adv Healthc Mater. 2024; 13: e2400645.
15.
Caron E, Vincent K, Fortier M-H, Laverdure J-P, Bramoullé A, Hardy M-P, et al.The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation.Mol Syst Biol. 2011; 7: 533.
16.
Valečka J, Almeida CR, Su B, Pierre P, Gatti E.Autophagy and MHC-restricted antigen presentation.Mol Immunol. 2018; 99: 163–70.
17.
Llibre A, Kucuk S, Gope A, Certo M, Mauro C.Lactate: a key regulator of the immune response.Immunity. 2025; 58: 535–54.
18.
Giovanelli P, Sandoval TA, Cubillos-Ruiz JR.Dendritic cell metabolism and function in tumors.Trends Immunol. 2019; 40: 699–718.
19.
Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al.Lipid accumulation and dendritic cell dysfunction in cancer.Nat Med. 2010; 16: 880–6.
20.
Kaymak I, Luda KM, Duimstra LR, Ma EH, Longo J, Dahabieh MS, et al.Carbon source availability drives nutrient utilization in CD8+ T cells.Cell Metab. 2022; 34: 1298–311.e6.
Appendix
Less
Year 2025 volume 22 Issue 11
PDF
35
20
Cite this Article
BibTeX
Article Info
doi: 10.20892/j.issn.2095-3941.2025.0445
  • Receive Date：2025-08-02
  • Online Date：2026-04-03
  • Published：2025-11-15
Article Data
Affiliations
History
  • Received：2025-08-02
  • Accepted：2025-09-08
Affiliations
    Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 440100, China

Corresponding:

References
Share
https://castjournals.cast.org.cn/joweb/cbm/EN/10.20892/j.issn.2095-3941.2025.0445
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House